Polyclonal Antibody to Angiotensin I Converting Enzyme 2 (ACE2)
| Code | Size | Price |
|---|
| PAB886Hu01-20ul | 20ul | £66.00 |
Quantity:
| PAB886Hu01-100ul | 100ul | £113.00 |
Quantity:
| PAB886Hu01-200ul | 200ul | £148.00 |
Quantity:
| PAB886Hu01-1ml | 1ml | £325.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
ACEH; ACEII; ACE-II; Peptidyl-Dipeptidase A; ACE-related carboxypeptidase; Angiotensin-converting enzyme homolog; Metalloprotease MPROT15
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Angiotensin I Converting Enzyme 2
Reactivity:
Po;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;<br/>Immunohistochemistry: 5-20ug/mL;<br/>Immunocytochemistry: 5-20ug/mL;<br/>Optimal working dilutions must be determined by end user.
References
https://www.researchsquare.com/article/rs-129298/latest.pdf; https://onlinelibrary.wiley.com/doi/full/10.1002/cti2.1245; https://www.mdpi.com/1999-4915/13/6/1133;
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Angiotensin I Converting Enzyme 2 (ACE2) | RPB886Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||